Overview

PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients

Status:
Unknown status
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine whether rifalazil can significantly increase peak walking time (PWT) in patients with peripheral arterial disease (PAD).
Phase:
Phase 3
Details
Lead Sponsor:
ActivBiotics
Treatments:
KRM 1648
Rifamycins